

1 Development and Clinical Validation of Swaasa AI Platform for screening 2 and prioritization of Pulmonary TB

3

4 Dr. Gayatri Devi Yellapu¹, Gowrisree Rudraraju*², Narayana Rao Sripada², Baswaraj Mamidgi²,
5 Charan Jalukuru ², Priyanka Firmal², Venkat Yechuri², Dr. Sowmya Varanasi¹, Dr. Venkata Sudhakar
6 Peddireddi¹, Dr. Devi Madhavi Bhimarasetty¹, Dr. Sidharth Kaniseti¹, Dr. Niranjana Joshi³, Dr Prasant
7 Mohapatra⁴, Dr. kiran Pamarthi¹

8 1 Andhra Medical College, Visakhapatnam, India

9 2 Salcit Technologies, Jayabheri Silicon Towers, Hyderabad India

10 3 C-CAMP

11 4 Department of Computer Science, University of California, Davis

12 *Corresponding author: gowri@salcit.in

13

14 **Keywords:** Pulmonary Tuberculosis (PTB), Cough signature, Convolutional Neural Network
15 (CNN), Feedforward Artificial Neural Network (FFANN), Machine learning

16 Abstract

17 Acoustic signal analysis has been employed in various medical devices. However, studies
18 involving cough sound analysis to screen the potential Pulmonary Tuberculosis (PTB)
19 suspects are very few. The main objective of this cross-sectional validation study was to
20 develop and validate the Swaasa AI platform to screen and prioritize at risk patients for PTB
21 based on the signature cough sound as well as symptomatic information provided by the
22 subjects. The voluntary cough sound data was collected at Andhra Medical College-India. An
23 Algorithm based on multimodal Convolutional Neural Network (CNN) architecture and
24 Feedforward Artificial Neural Network (FFANN) (tabular features) was built and validated
25 on a total of 567 subjects, comprising 278 positive and 289 negative PTB cases. The output
26 from these two models was combined to detect the likely presence (positive cases) of PTB. In
27 the clinical validation phase, the AI-model was found to be 86.82% accurate in detecting the
28 likely presence of PTB with 90.36% sensitivity and 84.67% specificity. The pilot testing of
29 model was conducted at a peripheral health care centre, RHC Simhachalam-India on 65
30 presumptive PTB cases. Out of which, 15 subjects truly turned out to be PTB positive with a
31 Positive Predictive Value of 75%. The validation results obtained from the model are quite
32 encouraging. This platform has the potential to fulfil the unmet need of a cost-effective PTB
33 screening method. It works remotely, presents instantaneous results, and does not require a
34 highly trained operator. Therefore, it could be implemented in various inaccessible, resource-
35 poor parts of the world.

36

37

38 **Introduction**

39 Tuberculosis (TB) is the world's second leading airborne infectious disease after COVID-19.

40 Unlike COVID the causative agent of TB is a bacterium, *Mycobacterium tuberculosis*

41 (MTB). However, both the infections mainly affect the respiratory system. Although the

42 bacteria have the capability to cause infection in various body parts. Pulmonary Tuberculosis

43 (PTB) along with Extra pulmonary tuberculosis (EPTB) are the active form of infection,

44 which displays symptoms such as fever, night sweat, weight loss and cough ^{1,2}. In 2020, the

45 World Health Organization globally reported nearly 10 million active TB cases and 1.5

46 million TB related mortalities. Although, TB is curable and preventable, the number of active

47 cases is still high in various low income, developing countries including India. An active

48 PTB patient can infect nearly ten to fifteen people every year ³. Currently there are several

49 methods for diagnosing presumptive as well as active PTB cases, such as sputum staining,

50 chest X-ray (CXR) and sputum cartridge based nucleic acid amplification test (CB-NAAT) or

51 sputum GeneXpert test. However, all these methods are very expensive, require proper lab

52 setting and trained technicians. Therefore, quick, and inexpensive mass screening methods ⁴

53 are required for reducing the transmission of infection by providing timely diagnosis

54 followed by appropriate treatment regime ^{5,6}.

55 Cough is a common symptom of respiratory disease and is caused by an explosive expulsion

56 of air to clear the airways ⁷. It is a significant feature of pulmonary tuberculosis and results in

57 the release of airborne particles into the environment ^{8,9}. There are commonly two types of

58 coughs i.e., wet and dry. Coughs are classified as wet when they have auditory characteristics

59 that are suggestive of mucus, and dry when there is no discernible wetness ¹⁰. It has also been

60 postulated that the glottis behaves differently under different pathological conditions, which

61 makes it possible to distinguish coughs originating from different underlying conditions such

62 as asthma, bronchitis, and pertussis (whooping cough) ¹¹. Since coughing is a dominant

63 symptom of PTB, there are reports which suggest that the coughing sound of an individual
64 with pulmonary TB has some unique characteristic features that distinguish the diseased
65 condition from the normal scenario¹²⁻¹⁴. Still, a lot of research is needed to fully explore and
66 decode the information contained in the cough sound to use it as an indicator of the
67 underlying disease.

68 The recent application of Artificial Intelligence (AI) and advances of ubiquitous computing
69 for respiratory disease prediction has created an auspicious trend and myriad of future
70 possibilities in the medical domain¹⁵⁻¹⁷. There is an expeditiously emerging trend of
71 Machine learning (ML) and Deep Learning (DL)-based algorithms exploiting cough
72 signatures¹⁸. Cough analysis approaches are primarily subjective and are affected by the
73 limitations of human perception. Audiometric analysis of cough (digital signal) provides
74 essential information about characteristics of cough sounds in different respiratory
75 pathological conditions. Several studies have been conducted in the past to collect and
76 analyse cough sound data for PTB pre-screening and triaging using mobile devices.
77 However, there are some missing links in terms of selecting the subjects, collecting the cough
78 data and lack of proper technical/ clinical validations to scale up these tools for mass
79 screening of PTB subjects^{8,9,13,19,20}.

80 Our study provides a holistic approach by developing, validating, and testing the “Swaasa AI
81 platform” to screen and prioritize the potential PTB cases. It is a SaMD (Software as a
82 Medical Device) that evaluates respiratory health using a 10-second cough sound recording,
83 serving as a quick Point of Care tool. It effectively prioritizes at-risk patients for molecular
84 testing when used as a screening and triaging tool. As opposed to majority of the previous
85 reports that utilized the crowdsource cough sound database for training their model, we have
86 conducted the data collection from 567 unique subjects for our model derivation as well as
87 validation phase in a proper clinical setting. Hence, our data have cough recordings collected

88 from various unique subjects to build a robust model. Unlike others, we have trained two
89 parallel models i.e., Convolutional Neural Network (CNN) model with Mel spectrograms and
90 Feedforward Artificial Neural Network (FFANN or tabular) model with primary as well as
91 secondary features and merged the final layer to build a combined logic. In the validation
92 phase, the AI-model was found to be 86.82% accurate in detecting the likely presence of PTB
93 with 90.36% sensitivity and 84.67% specificity. Therefore, it satisfies the specificity (70%)
94 and sensitivity (90%) criteria set by the World Health Organisation (WHO) for a community-
95 based mass TB screening test¹⁴. The results obtained by the model are very promising with a
96 scope to make it scalable for quick, cost-effective, and non-invasive screening of PTB cases.
97 A large-scale study will further help us to improvise the accuracy of the platform for making
98 it more reliable for screening genetically diverse subjects under different environmental
99 conditions.

100 **Materials and Methods**

101 **Sample size estimation**

102 To calculate the adequate sample size for our study, we used a simple formula that required
103 us to select appropriate values for several assumptions. The formula used was
104 $n = Z^2 * P(1-P) / d^2$, where n represented the sample size, Z was the statistic corresponding to the
105 level of confidence, P was the expected prevalence, and d was the precision corresponding to
106 the effect size²¹. By using this formula, we were able to determine an appropriate sample
107 size for our study. These many number of subjects were appropriate for validating if the
108 device could detect PTB respiratory conditions with a 90% sensitivity on considering a 1%
109 error for a 95% confidence interval (CI) and a prevalence of 0.75% as the highest prevalence
110 of PBT in India is 0.747% (747 per 100,000 population)²². In total 567 subjects were
111 recruited, out of which 50.9% subjects were classified as controls. The control group

112 consisted of both healthy individuals and those who displayed respiratory disease symptoms
113 but tested negative for PTB via CB-NAAT. These respiratory conditions included asthma,
114 Chronic Obstructive Pulmonary Disease (COPD), Interstitial lung disease (ILD), and
115 pneumonia. The number of TB records were calculated based on disease prevalence. In order
116 to avoid potential bias in the model, it was trained using an equal number of TB and non-TB
117 records.

118 **Data Collection**

119 The cough data has been collected at Andhra Medical College (AMC), Visakhapatnam, India
120 as part of the clinical study “Swaasa Artificial Intelligence Platform for detecting the likely
121 presence of Pulmonary Tuberculosis”. The study was registered with Clinical Trials Registry-
122 India (CTRI/2021/09/036609) on 17th September 2021. The methods were performed in
123 accordance with relevant guidelines and regulations and approved by AMC- Institutional
124 Ethics Committee (IEC). Written informed consent was taken from all the enrolled subjects.
125 After getting the informed consent, the patient's demographic details and vitals were
126 collected. The patients were also interviewed as per the Part I of the St. George's Respiratory
127 Questionnaire (SGRQ) ²³, which primarily covers the symptoms they've had experienced
128 within the past few months or year. This was followed by cough sound collection by trained
129 health care personnel via a smartphone (Android or iPhone). To ensure the highest quality
130 data for analysis, several factors were taken into consideration before recording. The person
131 being recorded was given specific instructions to sit comfortably in a quiet place, hold the
132 recording device (which included smartphones and tablets from various manufacturers) 4-8
133 inches away from their mouth, and maintain a 90-degree angle with their face. They were
134 also instructed to take a deep breath and cough 2-3 times until the recording stopped, which
135 lasted for 10 seconds. However, since the collected data was from varying environments and
136 a variety of devices, it was important to control as many potential variables as possible.

137 Therefore, noise filtering was applied using a noise reduction algorithm. This algorithm
138 calculated the ratio of the power of observed signals at two microphones for smartphones
139 with two or more built-in microphones, and then calculated the spectral gain function based
140 on the power level ratio using the sigmoid function. The result was a denoised audio
141 recording. For smartphones with a single built-in microphone, noise filtering was not applied
142 during the recording. Instead, a noise removal technique was applied during pre-processing.
143 This involved subtracting the noise audio clip (which contained background noise such as
144 electronic noise, multiple people talking, and fan sound) from the signal audio clip (which
145 contained the cough). The noise removal technique isolated the signal using Fast Fourier
146 Transform, removing the background noise and resulting in a cleaner recording. Valid coughs
147 were detected using a cough/non-cough classifier, which screened the dataset for coughs with
148 high background noise. If a recording did not meet the minimum required valid coughs, a
149 message would appear on the mobile screen instructing the person to give another recording
150 following the instructions. Overall, these processes standardized the dataset, making it
151 suitable for analysis.

152 During the audio recording process, we implemented several safety measures to prevent the
153 transmission of disease. All subjects were required to wear a surgical mask while providing
154 the audio recordings, in order to limit the spread of germs through water droplets during
155 coughing. After each recording, the phone used for recording was cleaned using one of three
156 methods. A disinfectant wipe was used to clean the phone, or alternatively, a damp
157 microfiber cloth dipped in soapy water was used if the phone was waterproof. Another option
158 was to use a mobile sanitizer to clean the phone. These measures helped to maintain a clean
159 and safe environment during the data collection process.

160 Following the cough sample collection, patients were subjected for CB-NAAT and chest X-
161 Ray (CXR P/A) view for diagnosis of PTB. The data distribution across different gender and

162 age groups is presented in Figure 1. The inclusion criteria were that a patient must be of (a)
163 age ≥ 18 years and should display (b) symptoms suggestive of PTB (presumptive PTB).
164 Whereas patients with (a) age ≤ 18 years and who were (b) on ventilators support were
165 completely excluded from the current study. COVID precautionary and infection control
166 measures were followed strictly.

167 **Model development and training**

168 In the Phase 1 (Derivation phase) of the study, we aimed to develop and train a machine
169 learning-based model for the detection of pulmonary tuberculosis (PTB) using cough sounds.
170 The objective of this phase was to quantify the technical as well as analytical performance of
171 the device by establishing a unique cough signature for PTB. A total of 195 PTB positive
172 cases were recruited for the derivation phase, and audio cough recordings were collected. In
173 addition, 152 non-PTB subjects were also included to train the model to distinguish between
174 PTB condition and normal healthy subjects as well as other respiratory disease scenarios.

175 Event extraction was carried out from the collected audio cough records using the moving
176 window signal standard deviation technique²⁴. A cough/non-cough classifier was used to
177 segregate the events into actual coughs and non-coughs such as silence, speech, fan sounds,
178 vehicle sounds like horn, and noise. A total of 3102 cough events were extracted at this step.
179 The features were extracted from the time as well as frequency domain of each cough event.
180 The important time domain features that were taken into consideration were Zero crossing
181 rate (ZCR) and Energy. The frequency domain features which were utilized for data analysis
182 are MFCC, Spectral centroid, Spectral bandwidth, and Spectral roll-off²⁵. The features were
183 extracted for each frame within the cough signal. Each frame was typically about 20 ms in
184 duration. The cough event duration can vary from anywhere between 200 ms to 700 ms.

185 The total features extracted were 209, that includes age, gender, 120 Mel Frequency Cepstral
186 coefficients (40 MFCC, 40 first derivatives of MFCC, 40 second order derivatives of
187 MFCC), 9 spectral features (spectral centroid, spectral roll-off, spectral bandwidth, dominant
188 frequency, spectral skewness, spectral kurtosis, spectral crest, spectral spread and spectral
189 entropy), 33 chroma features (11 chroma, 11 first derivatives of chroma, 11 second
190 derivatives of chroma), 18 contrast features (6 contrast, 6 first derivatives of contrast, 6
191 second derivatives of contrast), 15 tonnentz features (5 tonnentz, 5 first derivatives of
192 tonnentz, 5 second derivatives of tonnentz), 3 Zero-crossing rate (ZCR, first derivatives of
193 ZCR, second derivatives of ZCR), 3 Energy (Energy, first derivatives of energy, second
194 derivatives of energy), 3 skewness (skewness, first derivatives of skewness, second
195 derivatives of skewness), 3 kurtosis (kurtosis, first derivatives of kurtosis, second derivatives
196 of kurtosis). On these features, we did correlation analysis and recursive feature elimination
197 (RFE) to rank the feature according to their importance. Correlation-based feature selection
198 was used to reduce the feature size from 209 to 170, and highly correlated features were
199 removed to prevent overfitting and improve the performance of the model. Primary features
200 include all the 170 features. The secondary features included age (categorized), gender,
201 symptoms, cough type (dry/wet), and cough duration. The cough type is derived from the
202 primary features and cough duration is derived from audio signal. The CNN model is trained
203 with the Mel spectrograms of cough sounds. Whereas, both secondary and primary features
204 were used to train the FFANN model.

205 The CNN model used in the study was based on transfer learning using Resnet-34 with
206 imagenet for training on spectrograms. Whereas, the FFANN was utilized to process the
207 tabular data. The FFANN consisted of two hidden layers, with 400 and 300 neurons,
208 respectively. Each layer was followed by batch normalization. The selection of the number of
209 layers, number of neurons in each layer, and the activation functions were determined using

210 the Bayesian optimization method. The last fully connected layers of both models were
211 removed, and a new fully connected layer (merged layer) was added to predict the final
212 output. The merged layer consists of activation layers (Figure 2). This merging approach of
213 the last layers of the two models was named the combined logic. When the model is uncertain
214 about the likely detection of PTB as yes/no, it provides the output as inconclusive as
215 displayed in the block diagram in Figure 3, wherein PTB likely indicates TB positive and
216 PTB unlikely indicates TB negative condition.

217 Overall, the primary and secondary features were used to train feedforward neural network
218 models (tabular) and Mel spectrograms were used to train CNN and the combined logic
219 approach was used to merge the outputs of the two models. The correlation-based feature
220 selection was also used to improve the performance of the model.

221 During our study, we split the initial dataset into 80% training and 20% testing sets to assess
222 the performance of the machine learning model. In addition, we used the k-fold (K=10)
223 cross-validation approach to divide the training dataset into k subsets of data, which allowed
224 us to obtain a more robust estimate of the model's performance.

225 **Clinical validation of the Model**

226 After training the model, it was tested in the Phase 2 i.e., Clinical validation phase. A total of
227 220 presumptive PTB cases were recruited and subjected to the screening test using the
228 model. The results were compared with diagnosis based on sputum CB-NAAT test or
229 radiological diagnosis, which are considered classical gold standard diagnostic methods. A
230 total of 98% of the subjects underwent sputum CB-NAAT testing for the diagnosis of TB. In
231 cases where the results of CB-NAAT testing were unclear for the remaining 2% of subjects, a
232 repeat test was performed. If the results remained inconclusive after the second test, fresh

233 sputum samples were collected. Additional tests such as acid-fast bacilli (AFB) staining, and
234 chest X-ray (CXR) were performed to confirm the TB status of the patients.

235 The consolidated test summary sheet was generated, which contained the results obtained
236 from the classical gold standard diagnosis methods along with the model's output. Both the
237 results were then compared by a statistician.

238 **External validation of the Model**

239 In Phase 3 (Pilot Phase), the model was externally validated to evaluate its effectiveness as a
240 screening tool for PTB detection prior to clinical diagnosis. The sample size for this phase
241 consisted of 65 individuals who were identified as presumptive PTB cases and recruited from
242 a peripheral healthcare center, RHC Simhachalam. The effectiveness of the model was
243 measured by calculating the ratio of patients truly diagnosed as PTB positive via standard
244 lab-based diagnostic techniques to all those who were predicted to be PTB positive via the
245 AI-based model. The diagnostic performance of the model was evaluated using metrics such
246 as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV),
247 and accuracy. To assess the effectiveness of the model, a data analysis strategy similar to that
248 used in phase 2 was employed. The AI-based model was compared with classical gold
249 standard diagnostic methods, such as sputum CB-NAAT testing or radiological diagnosis,
250 and the results were analysed using statistical methods.

251 **LIME Representation**

252 In Local interpretable model-agnostic explanations (LIME) representation ²⁶, the green part
253 shows where the model reacted positively for a particular class and red parts highlights where
254 it reacted negatively. It explains the prediction by presenting textual or visual artefacts that
255 provide qualitative understanding of the relationship between the instance's components (e.g.,
256 words in text, patches in an image) and the model's prediction.

257 **Statistical analysis**

258 The comprehensive evaluation of the model performance on the test set includes accuracy
259 sensitivity, specificity, positive prediction value (PPV), negative predictive values (NPV) and
260 ROC. To measure the variability around these parameters, we used 95% confidence intervals
261 using the Clopper–Pearson method ²⁷. To better understand the performance of the model in
262 screening PTB subjects, we also calculated confusion metrics on the entire test set.

263 **Results:**

264 **Patient population in Model derivation phase**

265 Cough sound data was collected from 195 subjects PTB positive subjects and 152 PTB
266 negative subjects in the derivation phase. Among 195 subjects, 65% were male and 35%
267 were female, with age ranging from 18 years to 64 & above. Subjects were confirmed with
268 TB by standard diagnosis methods. In this phase multiple data points were collected from the
269 subjects. Each data point was called a record. A total of 597 cough records were collected
270 from 195 patients. The data was annotated with disease condition as PTB i.e., PTB likely as
271 “yes”. For PTB unlikely, data representing other respiratory disease conditions was added
272 from the pre-existing labelled datasets (collected as a part of earlier studies) in appropriate
273 propositions ²⁵.

274 The features listed in Table 1 depicts the mean value of the features extracted from individual
275 frames, where we have considered normal as well as respiratory diseases data other than PTB
276 from our previous validation study conducted at Apollo Hospitals, Hyderabad ²⁵.

277 **LIME data comparison**

278 Spectral content is the distribution of audio signal based on its frequency w.r.t time, where
279 high spectral content emphasizes that the energy of the cough bout remains same throughout

280 the signal, whereas low spectral content corresponds to the conditions where the energy of
281 the cough decreases with time. We observed that conditions like COPD and ILD carried very
282 low spectral frequencies as compared to Asthma, which has a medium spectral frequency. On
283 the other hand, we detected a very high spectral content for diseases where mucus
284 accumulation in the airways and fluid accumulation in parenchyma region was present such
285 as, PTB. Features like high spectral content brought uniqueness in the PTB cough, which
286 differentiates it from the other respiratory diseases.

287 Thorough feature analysis of the cough sounds highlighted that the cough sounds could
288 distinguish diseases. Variation in the cough duration and frequency distribution alters with
289 the pathological conditions of the respiratory system^{9,28}.

290 We have enlisted a few examples of cough signatures, cough spectrograms and related LIME
291 maps for different respiratory diseases, including PTB in Table 2. It is evident from the LIME
292 maps that frequency distribution of the coughs is unique for each disease. To be specific, both
293 Asthma & ILD have negative reactions in high frequency regions. TB has a positive reaction
294 in the high frequency region and in the low frequency region. Normal cough signature is
295 widely spread. However, it is not like other diseased conditions, where it has a strong patch
296 around a given region. Similarly in the first column of the table, the variation of the
297 amplitudes of the cough from bout to bout is different in coughs related to different diseases.
298 As amplitudes vary, energy also varies from bout to bout.

299 From the feature analysis we conclude that PTB related cough has a unique signature, and it
300 is captured by the features extracted from the cough, which can be identified by a machine
301 learning model.

302 **Performance of Combined logic Model**

303 Initially, the training data i.e., 3102 coughs which were extracted from 597 records collected
304 from 195 subjects was internally divided into training and validation as required to build as
305 well as optimize the model performance based on K-fold cross validation technique. The
306 performance of our model was evaluated using k-fold cross validation, with k set to 10. The
307 metric used for evaluation was the Area Under the Curve of the “Receiver Operating
308 Characteristic (AUCROC) curve, which provides a measure of the model's ability to
309 distinguish between positive and negative samples. The obtained AUC score was 0.98,
310 indicating that our model is highly effective in making accurate predictions. Figure 4 shows
311 the representative ROC curve of the best performing fold among the 10 cross validation
312 folds. In machine learning model, attribute like learning function, activation function were
313 fixed for learning. Hence, the dataset was divided into subsets and the model was trained with
314 each subset to validate the model.

315 Further, the data collected in the derivation phase have been divided into 80% train and 20%
316 test, when the test data was run through the classifier. We obtained four outcomes as enlisted
317 in Table 3 i.e., 102 True positives (TP), 20 False Negatives (FN); 22 False Positives (FP) and
318 128 True Negatives (TN), that corresponds to 85% accuracy, 84% sensitivity and 85%
319 specificity.

320 A total of 220 subjects participated in the validation phase, out of which 83 subjects were
321 found to be PTB positive and 137 subjects PTB negative by standard diagnostic methods.
322 Only one cough record was collected from each subject in this phase. We achieved an AUC
323 (Area Under the ROC Curve) of 0.94 (Figure 5). Confusion matrix for validation phase of the
324 model is illustrated in Table 4, where the row represents the actual label, and the column
325 represents predicted label. For the Validation phase we achieved an accuracy of 86.82% with
326 90.36% sensitivity and 84.67% specificity (Table 5).

327 **Model Output in the Pilot phase**

328 Pilot testing was done on a total of 65 subjects. The patients approaching the testing centre
329 with symptoms of cough suggestive of possible pulmonary tuberculosis are assessed for
330 eligibility. Patient's demographic details and vitals were collected and interviewed as per the
331 SGRQ questionnaire. This is followed by cough sound collection by trained health care
332 personnel.

333 Among 65 subjects, the model was able to identify 20 subjects as having a likely presence of
334 TB. Out of these 20 subjects, 15 truly turned out to be TB positive with a Positive predictive
335 value (PPV) of 75%. The confusion matrix for pilot testing phase is listed in Table 6. The
336 model obtained a high AUC score of 0.90. Figure 6 shows the ROC curve of the model's
337 ability to distinguish between positive and negative samples.

338 When compared to the existing classical methods, screening of PTB patients by the model
339 saved a significant amount of time. Additionally, it does not require any trained
340 professionals, the testing can be done by a community healthcare worker. The worker did not
341 require any specific hardware or any other consumables. A smartphone with an internet
342 connection is enough to conduct the test.

343 **Discussion**

344 Several studies have been conducted in the past to deploy the information contained in the
345 cough sound to detect and predict different disease outcomes such as Asthma, Pneumonia,
346 COPD, bronchitis, and lung-cancer^{10,29-31}. Nowadays, due to the increasing COVID-19
347 cases, there has been a tremendous boost in the use of ML/DL frameworks to determine the
348 presence of SARS-CoV-2 infection via cough sample analysis. This is because cough is one
349 of the most prominent symptoms for the diseases that primarily affect the respiratory system.
350 Numerous studies have shown that cough analysis can accurately predict COVID-19^{32,33}.

351 However, there are only a handful of clinical trials that emphasise the association of cough to
352 the underlying Pulmonary TB condition ^{12–14,20}. Most of the previously developed tools were
353 utilizing the logistic regression methods to build the model. However, in the current study,
354 we developed the model by combining the final output layers of the two separate models i.e.,
355 FFANN model (training input: primary and secondary features) and CNN model (training
356 input: Mel spectrograms) because it gave us far better prediction outcome as compared to the
357 either logical regression or CNN model used alone by other groups ^{13,14,20}. We conducted the
358 pilot screening on a comparatively large cohort, whereas previous studies were performed on
359 a smaller scale. A pilot study conducted in Peru focused on analysing cough sounds for
360 providing a foundation to support larger-scale studies of coughing rates over time for TB
361 patients undergoing treatment ²⁰. A similar cough sound analysis study was undertaken in
362 South Africa for automatically classifying coughing sounds, which could be a viable low-cost
363 and low-complexity screening method for PTB ¹³.

364 The approach of the current study is different with respect to the previously published data in
365 terms of the amount of data collected to build and train the model. As compared to the
366 maximum AUC of 0.94 achieved in a similar study upon utilizing only 23 features and with
367 less dataset, we have utilized 170 features while training the model and achieved an AUC of
368 0.84 on a dataset comprising TB and non-PTB, where non-PTB includes other important
369 diseases like Asthma, COPD, COVID-19, Pneumonia as well as healthy subjects ¹⁴. Having a
370 greater number of latent features helps in distinguishing the signature better. Our model
371 achieved an accuracy of 86.82% with 90.36% sensitivity and 84.67% specificity in the
372 clinical validation phase. We conducted the pilot testing in a real primary care setting to test
373 the accuracy of the tool. Upon deployment as a screening and triaging tool prior to molecular
374 testing, the model was proven statistically effective in prioritizing at-risk patients for

375 confirmatory testing. In the pilot phase also, the model achieved a positive prediction value
376 of 75% in a clinical setup at a tertiary care hospital.

377 Considering the performance of the present diagnostic tests for PTB, our model's technical
378 and clinical validation results are quite encouraging, given the device is primarily intended to
379 be used as a screening tool and helps in prioritizing and fast tracking the patients for
380 subjecting them to the standard reference tests for confirmation of diagnosis of PTB.

381 During our study we observed that on an average 10 to 12 patients are diagnosed with
382 extensive PTB with severe parenchymal damage, respiratory failure and poor lung function
383 every month at a remote community health centre in India. Most of these patients belong to
384 tribal areas. The delay in diagnosis is mainly due to lack of awareness, and social inhibitions
385 in reaching a doctor or a peripheral health worker. We believe that this model will help in
386 reducing the gap in accessibility for the much-needed population.

387 **Data availability**

388 Due to the nature of this research, participants of this study did not agree for their data to be
389 shared publicly. However, the detailed analysis can be shared by NRS upon reasonable
390 request.

391 **Author contributions**

392 GDY and DMB defined study protocol, including the study design and methodology. NRS
393 conceptualized the idea of using cough sounds for screening and diagnosing respiratory
394 problems. GR performed literature review and data analysis. BM and CJ were involved in
395 device development. VY created a value proposition for the device. VSP assisted in
396 executing the project at AMC by providing all the resources and extending research
397 capabilities. SV, SK and KP performed data analysis, sample size estimation and result
398 analysis. PM provided subject matter expertise. GR and PF wrote the manuscript. All the
399 authors provided intellectual inputs and helped in preparing the manuscript.

400 **Conflict of interest**

401 The authors declare no commercial or financial conflict of interest.

402 **Acknowledgement**

403 This study is supported by the UK Government (British High Commission, New Delhi). This
404 is a commissioned research report on commercial terms between C-CAMP and the UK
405 Government (British High Commission, New Delhi). We would also like to acknowledge the
406 team from Andhra Medical College Visakhapatnam, Government TB & Chest Hospital
407 Visakhapatnam for all the support provided

408 **References**

- 409 1. Al Lawati, R. *et al.* COVID-19 and Pulmonary Mycobacterium Tuberculosis
410 Coinfection. *Oman Med. J.* **36**, e298–e298 (2021).
- 411 2. Pai, M. *et al.* Tuberculosis. *Nat. Rev. Dis. Prim.* **2**, 1–23 (2016).
- 412 3. WHO. *Global tuberculosis report 2021*. Geneva: World Health Organization; 2021.
413 Licence: CC BY-NC-SA 3.0 IGO. (2021).
- 414 4. WHO. *Systematic screening for active tuberculosis*. World Health Organization
415 (2013).
- 416 5. Migliori, G. B. *et al.* Reducing tuberculosis transmission: a consensus document from
417 the World Health Organization Regional Office for Europe. *Eur. Respir. J.* **53**, 1–18
418 (2019).
- 419 6. Gill, C. M., Dolan, L., Piggott, L. M. & McLaughlin, A. M. New developments in
420 tuberculosis diagnosis and treatment. *Breathe* **18**, 1–15 (2022).
- 421 7. Chung, K. F. & Pavord, I. D. Prevalence, pathogenesis, and causes of chronic cough.
422 *Lancet* **371**, 1364–1374 (2008).
- 423 8. Simonsson, B. G., Jacobs, F. M. & Nadel, J. A. Role of Autonomic Nervous System
424 and the Cough Reflex in the Increased Responsiveness of Airways in Patients with
425 Obstructive Airway Disease. *J. Clin. Invest.* **46**, 1812–1818 (1967).
- 426 9. Turner, R. D. & Bothamley, G. H. Cough and the Transmission of Tuberculosis. *J.*
427 *Infect. Dis.* **211**, 1367–1372 (2015).
- 428 10. Swarnkar, V. *et al.* Automatic Identification of Wet and Dry Cough in Pediatric
429 Patients with Respiratory Diseases. *Ann. Biomed. Eng.* **41**, 1016–1028 (2013).
- 430 11. Kaplan, A. G. Chronic Cough in Adults: Make the Diagnosis and Make a Difference.
431 *Pulm. Ther.* **5**, 11–21 (2019).
- 432 12. Proaño, A. *et al.* Protocol for studying cough frequency in people with pulmonary

- 433 tuberculosis. *BMJ Open* **6**, 1–9 (2016).
- 434 13. Botha, G. H. R. *et al.* Detection of tuberculosis by automatic cough sound analysis.
435 *Physiol. Meas.* **39**, 045005 (2018).
- 436 14. Pahar, M. *et al.* Automatic cough classification for tuberculosis screening in a real-
437 world environment. *Physiol. Meas.* **42**, 105014 (2021).
- 438 15. Armstrong, S. The computer will assess you now. *BMJ* **355**, 1–2 (2016).
- 439 16. The Lancet. Artificial intelligence in health care: within touching distance. *Lancet* **390**,
440 2739 (2017).
- 441 17. Topalovic, M. *et al.* Artificial intelligence outperforms pulmonologists in the
442 interpretation of pulmonary function tests. *Eur. Respir. J.* **53**, 1–11 (2019).
- 443 18. Ijaz, A. *et al.* Towards using cough for respiratory disease diagnosis by leveraging
444 Artificial Intelligence: A survey. *Informatics Med. Unlocked* **29**, 1–28 (2022).
- 445 19. Kik, S. V., Denking, C. M., Casenghi, M., Vadnais, C. & Pai, M. Tuberculosis
446 diagnostics: which target product profiles should be prioritised? *Eur. Respir. J.* **44**,
447 537–540 (2014).
- 448 20. Larson, S. *et al.* Validation of an Automated Cough Detection Algorithm for Tracking
449 Recovery of Pulmonary Tuberculosis Patients. *PLoS One* **7**, 1–10 (2012).
- 450 21. Pourhoseingholi, M. A., Vahedi, M. & Rahimzadeh, M. Sample size calculation in
451 medical studies. *Gastroenterol. Hepatol. from Bed to Bench* **6**, 14–17 (2013).
- 452 22. National TB elimination programme Central TB Division. *National TB Prevalence*
453 *Survey in India 2019 - 2021. Ministry of Health and Family Welfare*
454 <https://tbcindia.gov.in/showfile.php?lid=3659> (2021).
- 455 23. Jones, P. W., Quirk, F. H. & Baveystock, C. M. The St George’s Respiratory
456 Questionnaire. *Respir. Med.* **85**, 25–31 (1991).
- 457 24. Barry, S. J., Dane, A. D., Morice, A. H. & Walmsley, A. D. The automatic recognition










- 458 and counting of cough. *Cough* **2**, 8 (2006).
- 459 25. Rudraraju, G. *et al.* Cough sound analysis and objective correlation with spirometry
460 and clinical diagnosis. *Informatics Med. Unlocked* **19**, 1–11 (2020).
- 461 26. Ribeiro, M., Singh, S. & Guestrin, C. “Why Should I Trust You?”: Explaining the
462 Predictions of Any Classifier. in *Proceedings of the 2016 Conference of the North
463 American Chapter of the Association for Computational Linguistics: Demonstrations*
464 1135–1144 (Association for Computational Linguistics, 2016). doi:10.18653/v1/N16-
465 3020.
- 466 27. Clopper, C. J. & Pearson, E. S. The Use of Confidence or Fiducial Limits Illustrated in
467 the Case of the Binomial. *Biometrika* **26**, 404–413 (1934).
- 468 28. Belkacem, A. N., Ouhbi, S., Lakas, A., Benkhelifa, E. & Chen, C. End-to-End AI-
469 Based Point-of-Care Diagnosis System for Classifying Respiratory Illnesses and Early
470 Detection of COVID-19: A Theoretical Framework. *Front. Med.* **8**, 1–13 (2021).
- 471 29. Abeyratne, U. R., Swarnkar, V., Setyati, A. & Triasih, R. Cough Sound Analysis Can
472 Rapidly Diagnose Childhood Pneumonia. *Ann. Biomed. Eng.* **41**, 2448–2462 (2013).
- 473 30. Xu, X. *et al.* Listen2Cough: Leveraging End-to-End Deep Learning Cough Detection
474 Model to Enhance Lung Health Assessment Using Passively Sensed Audio. *Proc.
475 ACM Interactive, Mobile, Wearable Ubiquitous Technol.* **5**, 1–22 (2021).
- 476 31. Klco, P., Kollarik, M. & Tatar, M. Novel computer algorithm for cough monitoring
477 based on octonions. *Respir. Physiol. Neurobiol.* **257**, 36–41 (2018).
- 478 32. Laguarda, J., Hueto, F. & Subirana, B. COVID-19 Artificial Intelligence Diagnosis
479 Using only Cough Recordings. *IEEE Open J. Eng. Med. Biol.* **1**, 275–281 (2020).
- 480 33. Pahar, M., Klopper, M., Warren, R. & Niesler, T. COVID-19 cough classification
481 using machine learning and global smartphone recordings. *Comput. Biol. Med.* **135**, 1–
482 10 (2021).
- 483


484 **Table 1:** Table showing mean values of the Zero crossing rate (ZCR), spectral centroid and
 485 dominant frequency of various disease conditions.

Disease Conditions	ZCR Mean values	Spectral centroid mean values	Dominant Frequency mean values
Normal	0.169	2809	2809
ILD	0.099	2053	2053
COPD	0.08	1947	1947
Asthma	0.112	2093	2093
Pneumonia	0.118	2249	2249
COVID	0.216	3135	3135
TB	0.178	2867	2867

486

487 **Table 2:** List of different respiratory diseases showing characteristic cough signature, cough
 488 spectrograms and related LIME maps.

Disease	Cough Signature	Spectrogram	LIME maps
PTB			
Asthma			
Normal			



489

490 **Table 3:** Data distribution into train data and test data along with final confusion matrix for
 491 the test data in derivation phase

Records	Train (cough records)	Test (cough records)	Total (cough records)
TB Likely - Yes	475	122	527
TB Likely - No	853	150	1003
Total	1328	272	1600
Percentage	83%	17%	100%

492

	TB Likely- Yes	TB Likely- No
TB- Yes	102 (TP)	20 (FN)
TB- No	22 (FP)	128 (TN)

493

494 **Table 4:** Confusion matrix for the validation phase

	TB Likely- Yes	TB Likely- No
TB- Yes	75 (TP)	8 (FN)
TB- No	21 (FP)	116 (TN)

495

496 **Table 5:** Performance metrics of the validation phase

Statistic	Value	95% CI
Sensitivity	90.36%	81.89% to 95.75%
Specificity	84.67%	77.53% to 90.25%

Positive Likelihood Ratio	5.90	3.95 to 8.79
Negative Likelihood Ratio	0.11	0.06 to 0.22
Disease Prevalence	37.73%	31.30% to 44.49%
Positive Predicate Value	78.12%	70.54% to 84.19%
Negative Predicate Value	93.55%	88.20% to 96.57%
Accuracy	86.82%	81.62% to 90.99%


497

498 **Table 6:** Confusion matrix for the pilot testing phase

	TB Likely- Yes	TB Likely- No
TB- Yes	15 (TP)	5 (FN)
TB- No	9 (FP)	36 (TN)

499


500 **Figure 1:** Data distribution in the derivation phase, validation phase and pilot testing.




501

502 **Figure 2:** Illustration of the combined logic - combining Feedforward Artificial Neural

503 Network (FFANN) model and Convolutional Neural Network (CNN) outputs



504 **Figure 3:** Block Diagram illustrating the flow of the TB prediction model




505

506

507 **Figure 4:** The representative graph for ROC curve, best among 10-fold validation of TB
508 prediction model built using derivation data.


509



522

523

524 **Figure 5:** The provided graph shows the best ROC curve of a TB prediction model
525 constructed using validation data.



537

538

539 **Figure 6:** The provided ROC curve illustrates the performance of a TB prediction model

540 constructed using pilot data

